Skip to main content

EASD 2019

55th EASD Annual Meeting coverage

Including news and expert commentaries on the VERIFY trial, DEFINE-HF trial, and PRIORITY study.


Expert interviews

09-20-2019 | Heart failure | Video | Article

Researcher comment: The DEFINE-HF trial results

Mikhail Kosiborod outlines the findings from the DEFINE-HF trial, and discusses the possible reasons why dapagliflozin had an impact on one primary endpoint but not the other (5:48).

09-20-2019 | Nephropathy | Video | Article

Expert commentary: The PRIORITY trial results

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

09-20-2019 | Insulin degludec | Video | Article

Researcher comment: The CONCLUDE trial

Athena Philis-Tsimikas discusses which patients may benefit the most from treatment with long-acting insulins, and how the data from CONCLUDE compare with real-world study findings (2:38).

09-19-2019 | Medications | Video | Article

Expert commentary: Trial results of imeglimin in type 2 diabetes

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

09-19-2019 | Vildagliptin | Highlight | Article

Expert commentary: The VERIFY trial results

Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).

09-19-2019 | Heart failure | Video | Article

Expert commentary: DAPA-HF and DEFINE-HF trial results

Lars Rydén discusses how the results of the DAPA-HF and DEFINE-HF trials will impact treatment decisions for patients with heart failure (6:38).

09-19-2019 | Heart failure | Video | Article

Researcher comment: The DAPA-HF trial results

John McMurray talks about the results of the DAPA-HF trial, discussing whether the benefits of dapagliflozin for patients with heart failure could be extended to other SGLT2 inhibitors, and the next steps for research (3:29).

More research news from EASD 2019

09-27-2019 | Heart failure | EASD 2019 | News

DAPA-HF analyses provide further insights into dapagliflozin efficacy

Analyses of metabolic, biomarker, and other outcomes from the DAPA-HF trial presented at the 55th EASD Annual Meeting in Barcelona, Spain, provide additional insights into the efficacy of dapagliflozin in patients with heart failure.

09-25-2019 | Heart failure | EASD 2019 | News

Cardiorenal disease the earliest, most serious CV manifestation in type 2 diabetes

Cardiorenal disease is the foremost cardiovascular complication in people with type 2 diabetes, researchers report at the 55th EASD Annual Meeting in Barcelona, Spain.

09-25-2019 | Hypoglycemia | EASD 2019 | News

Daytime hyperglycemia, nocturnal hypoglycemia remain problems for EDIC cohort

People with type 1 diabetes rarely achieve the current targets for blood glucose control, with nocturnal hypoglycemia remaining a particular concern, shows an analysis of the DCCT/EDIC cohort.

EASD 2019 clinical trial overviews

Get up to speed on the clinical trials headlining EASD 2019 with our brief overviews.

EASD 2019 session recommendations

The Medicine Matters diabetes Editorial Board share their symposia picks and reactions from EASD 2019.

Medicine Matters conference coverage is brought to you in partnership with medwireNews

Image Credits